Injectable weight-loss medicine for adults with obesity or overweight
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests whether people with obesity or overweight can safely and effectively give themselves the study medicine (called maridebart cafraglutide) at home using a pre-filled autoinjector pen. It is being studied as a weight-loss treatment for adults who have struggled to lose weight with diet and exercise alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your body mass index (BMI) must be 30 or higher, or between 27 and 30 with a weight-related health condition like high blood pressure, high cholesterol, sleep apnea, heart disease, or fatty liver disease.
- You must have tried at least one time to lose weight through diet and exercise.
- If you are a woman who can have children, you must use contraception during the trial.
- You must not have diabetes (type 1 or type 2), recent pancreatitis, or a history of medullary thyroid cancer.
- You must not have had weight-loss surgery or a weight-loss device, and your weight must have been stable (within 11 pounds) for the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two versions of an investigational weight-loss injection to see if they are absorbed similarly. It is an early-stage trial for adults with a BMI of 25 or higher who want to help improve future treatments.
This study tests a drug called Maridebart Cafraglutide for long-term weight management in people who completed a previous related trial. It looks at how well the drug works and its safety over time.
This study tests the long-term effects of a medication called maridebart cafraglutide for weight management. It is for people who already completed a 72-week study of this drug and want to continue treatment.
This study tests a new weekly injection (maridebart cafraglutide) to see if it helps lower the risk of heart problems in people with heart disease and overweight. It is for adults who have had a heart attack, stroke, or artery blockages and also have a BMI of 27 or higher.
This trial tests a medication called maridebart cafraglutide for people with heart failure (where the heart doesn't pump as well as it should) and obesity. The goal is to see if it can help improve symptoms and outcomes.
This study tests an oral medicine (semaglutide) to see if it helps adults with excess weight lose weight. It might offer an easier, pill-based treatment option for weight management.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.